Unstable mutations in the FMR1 gene and the phenotypes

Advances in Experimental Medicine and Biology

Volumn 769, Issue , 2012, Pages 78-114

  Loesch, Danuta ^a   Hagerman, Randi ^b  

^a LA TROBE UNIVERSITY   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIOXIDANT; ARBACLOFEN; ARIPIPRAZOLE; CLONIDINE; FRAGILE X MENTAL RETARDATION PROTEIN; GUANFACINE; MESSENGER RNA; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 5 ANTAGONIST; METABOTROPIC RECEPTOR ANTAGONIST; MINOCYCLINE; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; ATAXIA; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; BRAIN PSEUDOTUMOR; COGNITIVE DEFECT; FMR1 GENE; FRAGILE X ASSOCIATED PRIMARY OVARY INSUFFICIENCY; FRAGILE X ASSOCIATED TREMOR ATAXIA SYNDROME; FRAGILE X SYNDROME; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOTE; HUMAN; LEARNING DISORDER; LONG TERM DEPRESSION; LUPUS LIKE SYNDROME; MENTAL DISEASE; NAIL DISEASE; NERVE DEGENERATION; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; OVARY INSUFFICIENCY; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPIC VARIATION; PREMUTATION; PREVALENCE; PRIORITY JOURNAL; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DISCOLORATION; TOOTH DISCOLORATION; TREMOR; TRINUCLEOTIDE REPEAT; UNSPECIFIED SIDE EFFECT; CLINICAL FEATURE; DNA STRUCTURE; GENE; GENE FREQUENCY; GENE FUNCTION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; PARKINSONISM; PHENOTYPE; PROMOTER REGION;

EID: 84934443796     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5434-2_6     Document Type: Article

References (250)

1. Verkerk AJ, Pieretti M, Sutcliffe JS et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991; 65(5):905-914.
2. Lubs HA. A marker X chromosome. American Journal of Human Genetics 1969; 21(3):231-244.
3. Cronister A, Schreiner R, Wittenberger M et al. Heterozygous fragile X female: historical, physical, cognitive, and cytogenetic features. Am J Med Genet 1991; 38(2-3):269-274.
4. Sullivan AK, Marcus M, Epstein MP et al. Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod 2005; 20(2):402-412.
5. Wittenberger MD, Hagerman RJ, Sherman SL et al. The FMR1 premutation and reproduction. Fertil Steril 2007; 87(3):456-465.
6. Welt CK. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol (Oxf) 2008; 68(4):499-509.
7. Hagerman RJ, Leehey M, Heinrichs W et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001; 57:127-130.
8. Jacquemont S, Hagerman RJ, Leehey M et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. American Journal of Human Genetics 2003; 72(4):869-878.
9. Berry-Kravis E, Abrams L, Coffey SM et al. Fragile X-associated tremor/ataxia syndrome: clinical features, genetics and testing guidelines. Mov Disord 2007; 22(14):2018-2030.
10. Tassone F, Berry-Kravis E, eds. Fragile X-associated Tremor Ataxia Syndrome (FXTAS). New York, NY: Springer-Verlag New York Inc.; 2011.
11. Tassone F, Hagerman RJ, Taylor AK et al. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. American Journal of Human Genetics 2000; 66(1):6-15.
12. Hagerman PJ, Hagerman RJ. The fragile-X premutation: a maturing perspective. American Journal of Human Genetics 2004; 74(5):805-816.
13. Garcia-Arocena D, Hagerman PJ. Advances in understanding the molecular basis of FXTAS. Hum Mol Genet 2010; 19(R1):R83-R89.
14. Farzin F, Perry H, Hessl D et al. Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. J Dev Behav Pediatr 2006; 27(2 Suppl):S137-S144.
15. Aziz M, Stathopulu E, Callias M et al. Clinical features of boys with fragile X premutations and intermediate alleles. Am J Med Genet. in press 2003; 121B(1):119-127.
16. Clifford S, Dissanayake C, Bui QM et al. Autism spectrum phenotype in males and females with fragile X full mutation and premutation. Journal of Autism and Developmental Disorders 2007; 37(4):738-747.
17. Goodlin-Jones B, Tassone F, Gane LW et al. Autistic spectrum disorder and the fragile X premutation. J Dev Behav Pediatr 2004; 25(6):392-398.
18. Bailey DB Jr., Raspa M, Olmsted M et al. Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey. American Journal of Medical Genetics 2008; 146A(16):2060-2069.
19. Roberts JE, Bailey DB Jr., Mankowski J et al. Mood and anxiety disorders in females with the FMR1 premutation. Am J Med Genet B Neuropsychiatr Genet 2009; 150B(1):130-139.
20. Hessl D, Tassone F, Loesch DZ et al. Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. Am J Med Genet B Neuropsychiatr Genet 2005; 139B(1):115-121.
21. Cornish K, Kogan C, Turk J et al. The emerging fragile X premutation phenotype: evidence from the domain of social cognition. Brain and cognition 2005; 57(1):53-60.
22. Rodriguez-Revenga L, Madrigal I, Pagonabarraga J et al. Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Eur J Hum Genet 2009; 17(10):1359-1362.
23. Bourgeois JA, Coffey SM, Rivera SM et al. A review of fragile X premutation disorders: expanding the psychiatric perspective. J Clin Psychiatry 2009; 70(6):852-862.
24. Bourgeois J, Seritan A, Casillas E et al. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. J Clin Psychiatry 2010: doi: 10.4088/JCP.4009m05407blu, Published online by Physicians Postgraduate Press, Inc.
25. Grigsby J, Brega AG, Engle K et al. Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome. Neuropsychology 2008; 22(1):48-60.
26. Hashimoto RI, Backer KC, Tassone F et al. An fMRI study of the prefrontal activity during the performance of a working memory task in premutation carriers of the fragile X mental retardation 1 gene with and without fragile X-associated tremor/ataxia syndrome (FXTAS). Journal of Psychiatric Research 2010: doi:10.1016/j.jpsychires.2010.1004.1030.
27. Coffey SM, Cook K, Tartaglia N et al. Expanded clinical phenotype of women with the FMR1 premutation. American Journal of Medical Genetics 2008; 146A(8):1009-1016.
28. Hagerman RJ. Physical and behavioral phenotype. In: Hagerman RJ, Hagerman PJ, eds. Fragile X syndrome: Diagnosis, Treatment and Research, 3rd edition. Baltimore: The Johns Hopkins University Press; 2002:3-109.
29. Pieretti M, Zhang FP, Fu YH et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 1991; 66(4):817-822.
30. Tassone F, Hagerman RJ, Ikle DN et al. FMRP expression as a potential prognostic indicator in fragile X syndrome. Am J Med Genet 1999; 84(3):250-261.
31. Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev 2004; 10(1):31-41.
32. Comery TA, Harris JB, Willems PJ et al. Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc Natl Acad SciUSA 1997; 94(10):5401-5404.
33. Devys D, Lutz Y, Rouyer N et al. The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nature genetics 1993; 4(4):335-340.
34. Hinds HL, Ashley CT, Sutcliffe JS et al. Tissue specific expression of FMR-1 provides evidence for a functional role in fragile X syndrome. Nat Genet 1993; 3(1):36-43.
35. Irwin SA, Galvez R, Greenough WT. Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb Cortex 2000; 10(10):1038-1044.
36. Witt R, Kaspar B, Brazelton AD et al. Developmental localization of fragile X mRNA in rat brain. Soc Neurosci 1995; 21(1):293-296.
37. Weiler IJ, Greenough WT. Synaptic synthesis of the Fragile X protein: possible involvement in synapse maturation and elimination. Am J Med Genet 1999; 83(4):248-252.
38. Weiler IJ, Irwin SA, Klintsova AY et al. Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation PNAS 1997; 94(10):5395-5400.
39. Bassell GJ, Warren ST. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 2008; 60(2):201-214.
40. Dolen G, Carpenter RL, Ocain TD et al. Mechanism-based approaches to treating fragile X. Pharmacol Ther 2010; 127(1):78-93.
41. Oostra BA, Willemsen R. FMR1: a gene with three faces. Biochim Biophys Acta 2009; 1790(6):467-477.
42. Qin M, Kang J, Burlin TV et al. Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse. J Neurosci 2005; 25(20):5087-5095.
43. Darnell JC, van Dreische S, Zhang C et al. HITS-CLIP Identifies Specific Neuronal mRNA Targets of Translational Repression by the Fragile X Mental Retardation Protein, FMRP [abstract]. Paper presented at: Keystone Symposia 2010; Snowbird, UT.
44. Hagerman R, Hoem G, Hagerman P. Fragile X and autism: intertwined at the molecular level leading to targeted treatments. Mol Autism 2010; 1(1):12.
45. Zalfa F, Eleuteri B, Dickson KS et al. A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. Nat Neurosci 2007; 10(5):578-587.
46. Dahlhaus R, El-Husseini A. Altered neuroligin expression is involved in social deficits in a mouse model of the fragile X syndrome. Behavioural Brain Research 2010; 208(1):96-105.
47. Miyashiro KY, Beckel-Mitchener A, Purk TP et al. RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron 2003; 37(3):417-431.
48. Darnell JC, Mostovetsky O, Darnell RB. FMRP RNAtargets: identification and validation. Genes, Brain and Behavior 2005; 4(6):341-349.
49. Sharma A, Hoeffer CA, Takayasu Y et al. Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci 2010; 30(2):694-702.
50. Tassone F. mTOR up-regulation in patients with FXS [abstract]. Paper presented at: FRAXA Investigators meeting 2010; Durham, NH.
51. de Vries PJ. Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex. Neurotherapeutics 2010; 7(3):275-282.
52. Harris SW, Hessl D, Goodlin-Jones B et al. Autism profiles of males with fragile X syndrome. Am J Ment Retard 2008; 113(6):427-438.
53. Hatton DD, Sideris J, Skinner M et al. Autistic behavior in children with fragile X syndrome: prevalence, stability and the impact of FMRP. American Journal of Medical Genetics 2006; 140(17):1804-1813.
54. Kaufmann WE, Cortell R, Kau AS et al. Autism spectrum disorder in fragile X syndrome: communication, social interaction and specific behaviors. Am J Med Genet 2004; 129A(3):225-234.
55. Cordeiro L, Ballinger E, Hagerman R et al. Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization. Journal of Neurodevelopmental Disorders. in press.
56. Munir F, Cornish KM, Wilding J. A neuropsychological profile of attention deficits in young males with fragile X syndrome. Neuropsychologia 2000; 38(9):1261-1270.
57. Sullivan K, Hatton D, Hammer J et al. ADHD symptoms in children with FXS. American Journal of Medical Genetics 2006; 140(21):2275-2288.
58. Cornish KM, Turk J, Hagerman R. The fragile X continuum: new advances and perspectives. J Intellect Disabil Res 2008; 52(Pt 6):469-482.
59. Butler MG, Pratesi R, Watson MS et al. Anthropometric and craniofacial patterns in mentally retarded males with emphasis on the fragile X syndrome. Clinical genetics 1993; 44(3):129-138.
60. Hagerman RJ, Hull CE, Safanda JF et al. High functioning fragile X males: demonstration of an unmethylated fully expanded FMR-1 mutation associated with protein expression. Am J Med Genet 1994; 51(4):298-308.
61. Wright-Talamante C, Cheema A, Riddle JE et al. A controlled study of longitudinal IQ changes in females and males with fragile X syndrome. Am J Med Genet 1996; 64(2):350-355.
62. Tassone F, Hagerman RJ, Loesch DZ et al. Fragile X males with unmethylated, full mutation trinucleotide repeat expansions have elevated levels of FMR1 messenger RNA. Am J Med Genet 2000; 94(3):232-236.
63. Hall D, Pickler L, Riley K et al. Parkinsonism and cognitive decline in a fragile X mosaic male. Mov Disord 2010; 25(10):1523-1524.
64. Utari A, Adams E, Berry-Kravis E et al. Aging in fragile X syndrome. Journal of Neurodevelopmental Disorders 2010; 2(2):70-76.
65. de Vries BB, Wiegers AM, Smits AP et al. Mental status of females with an FMR1 gene full mutation. American Journal of Human Genetics 1996; 58(5):1025-1032.
66. Bennetto L, Pennington BF. Neuropsychology. In: Hagerman RJ, Hagerman PJ, eds. Fragile X Syndrome: Diagnosis, Treatment and Research. 3rd edition. Baltimore: Johns Hopkins University Press; 2002:206-248.
67. Angkustsiri K, Wirojanan J, Deprey LJ et al. Fragile X syndrome with anxiety disorder and exceptional verbal intelligence. American Journal of Medical Genetics 2008; 146(3):376-379.
68. Hagerman RJ, Berry-Kravis E, Kaufmann WE et al. Advances in the treatment of fragile X syndrome. Pediatrics 2009; 123(1):378-390.
69. Epstein J, Riley K, Sobesky W. The treatment of emotional and behavioral problems. In: Hagerman R, Hagerman P, eds. Fragile X Syndrome: Diagnosis, Treatment and Research. 3rd edition. Baltimore: The Johns Hopkins University Press; 2002:339-362.
70. Pembrey ME, Winter RM, Davies KE. A premutation that generates a defect at crossing over explains the inheritance of fragile X mental retardation. Am J Med Genet 1985; 21:709-717.
71. Fu YH, Kuhl DP, Pizzuti A et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 1991; 67(6):1047-1058.
72. Yu S, Mulley J, Loesch D et al. Fragile-X syndrome: unique genetics of the heritable unstable element. American Journal of Human Genetics 1992; 50(5):968-980.
73. Heitz D, Devys D, Imbert G et al. Inheritance of the fragile X syndrome: size of the fragile X premutation is a major determinant of the transition to full mutation. Journal of Medical Genetics 1992; 29(11):794-801.
74. Snow K, Doud LK, Hagerman R et al. Analysis of a CGG sequence at the FMR-1 locus in fragile X families and in the general population. Am J Hum Genet 1993; 53(6):1217-1228.
75. Vaisanen ML, Kahkonen M, Leisti J. Diagnosis of fragile X syndrome by direct mutation analysis. Hum Genet 1994; 93(2):143-147.
76. Nolin SL, Lewis FA 3rd, Ye LL et al. Familial transmission of the FMR1 CGG repeat. American Journal of Human Genetics 1996; 59(6):1252-1261.
77. Ashley-Koch AE, Robinson H, Glicksman AE et al. Examination of factors associated with instability of the FMR1 CGG repeat. Am J Hum Genet 1998; 63(3):776-785.
78. Nolin SL, Brown WT, Glicksman A et al. Expansion ofthe fragile X CGG repeat in females with premutation or intermediate alleles. American Journal of Human Genetics 2003; 72:454-464.
79. Brown WT, Houck GE Jr., Jeziorowska A et al. Rapid Fragile X carrier screening and prenatal diagnosis using a nonradioactive PCR test. JAMA 1993; 270(13):1569-1575.
80. Snow K, Tester DJ, Kruckeberg KE et al. Sequence analysis ofthe fragile X trinucleotide repeat: implications for the origin of the fragile X mutation. Hum Mol Genet 1994; 3(9):1543-1551.
81. Brown WT, Nolin S, Houck G Jr. et al. Prenatal diagnosis and carrier screening for fragile X by PCR. Am J Med Genet 1996; 64(1):191-195.
82. Youings SA, Murray A, Dennis N et al. FRAXA and FRAXE: the results of a five year survey. J Med Genet 2000; 37(6):415-421.
83. Dombrowski C, Levesque S, Morel ML et al. Premutation and intermediate-size FMR1 alleles in 10572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Hum Mol Genet 2002; 11(4):371-378.
84. Mitchell RJ, Holden JJ, Zhang C et al. FMR1 alleles in Tasmania: a screening study ofthe special educational needs population. Clinical genetics 2005; 67(1):38-46.
85. Zhou Y, Lum JM, Yeo GH et al. Simplified molecular diagnosis of fragile X syndrome by fluorescent methylation-specific PCR and GeneScan analysis. Clin Chem 2006; 52(8):1492-1500.
86. Khaniani MS, Kalitsis P, Burgess Tetal. An improved diagnostic PCR assay for identification of cryptic heterozygosity for CGG triplet repeat alleles in the Fragile X Gene (FMR1). Mol Cytogenet 2008; 1(1):5.
87. Filipovic-Sadic S, Sah S, Chen L et al. A novel FMR1 PCR method for the routine detection oflow-abundance expanded alleles and full mutations in fragile X syndrome. Clin Chem 2010; 56(3):399-408.
88. Fernandez-Carvajal I, Lopez Posadas B, Pan R et al. Expansion of an FMR1 grey-zone allele to a full mutation in two generations. J Mol Diagn 2009; 11(4):306-310.
89. Sullivan AK, Crawford DC, Scott EH et al. Paternally transmitted FMR1 alleles are less stable than maternally transmitted alleles in the common and intermediate size range. Am J Hum Genet 2002; 70(6):1532-1544.
90. Maddalena A, Richards CS, McGinniss MJ et al. Technical standards and guidelines for fragile X: the first of a series of disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics. Quality Assurance Subcommittee of the Laboratory Practice Committee. Genet Med 2001; 3(3):200-205.
91. Loesch DZ, Huggins R, Petrovic V et al. Expansion of the CGG repeat in fragile X in the FMR1 gene depends on the sex of the offspring. American Journal of Human Genetics 1995; 57(6):1408-1413.
92. Huggins RM, Loesch DZ, Qian GQ et al. Hierarchical Bayes model for random haplotype and family effects in the transmission of fragile-X. Genet Epidemiol 2004; 26(4):294-304.
93. Ashley AE, Sherman SL. Population dynamics of a meiotic/mitotic expansion model for the fragile X syndrome. Am J Hum Genet 1995; 57(6):1414-1425.
94. Zhong N, Ju W, Pietrofesa J et al. Fragile X "gray zone" alleles: AGG patterns, expansion risks and associated haplotypes. Am J Med Genet 1996; 64(2):261-265.
95. Eichler EE, Holden JJ, Popovich BW et al. Length of uninterrupted CGG repeats determines instability in the FMR1 gene. Nature genetics 1994; 8(1):88-94.
96. Eichler EE, Macpherson JN, Murray A et al. Haplotype and interspersion analysis of the FMR1 CGG repeat identifies two different mutational pathways for the origin of the fragile X syndrome. Hum Mol Genet 1996; 5(3):319-330.
97. Eichler EE, Nelson DL. Genetic variation and evolutionary stability of the FMR1 CGG repeat in six closed human populations. Am J Med Genet 1996; 64(1):220-225.
98. Zhong N, Yang W, Dobkin C et al. Fragile X gene instability: anchoring AGGs and linked microsatellites. Am J Hum Genet 1995; 57(2):351-361.
99. Yrigollen C, Long K, Tong T et al. The role of AGG interruptions in the stability of FMR1 gene. Paper presented at: 12th International Fragile X Conference; 2010; Detroit, MI.
100. Richards RI, Holman K, Kozman H et al. Fragile X syndrome: genetic localisation by linkage mapping of two microsatellite repeats FRAXAC1 and FRAXAC2 which immediately flank the fragile site. J Med Genet 1991; 28(12):818-823.
101. Zhong N, Kajanoja E, Smits B et al. Fragile X founder effects and new mutations in Finland. Am J Med Genet 1996a; 64(1):226-233.
102. Faradz SMH, Pattiiha MZ, Leigh DA et al. Genetic diversity at the FMR1 locus in the Indonesian population. Annals of Human Genetics 2000; 64(4):329-339.
103. Kunst CB, Warren ST. Cryptic and polar variation of the fragile X repeat could result in predisposing normal alleles. Cell 1994; 77(6):853-861.
104. Gunter C, Paradee W, Crawford DC et al. Re-examination of factors associated with expansion of CGG repeats using a single nucleotide polymorphism in FMR1. Hum Mol Genet 1998; 7(12):1935-1946.
105. Brightwell G, Wycherley R, Waghom A. SNP genotyping using a simple and rapid single-tube modification of ARMS illustrated by analysis of 6 SNPs in a population of males with FRAXA repeat expansions. Molecular and Cellular Probes 2002; 16(4):297-305.
106. Curlis Y, Zhang C, Holden JJ et al. Haplotype study of intermediate-length alleles at the fragile X (FMR1) gene: ATL1, FMRb and microsatellite haplotypes differ from those found in common-size FMR1 alleles. Hum Biol 2005; 77(1):137-151.
107. Toledano-Alhadef H, Basel-Vanagaite L, Magal N et al. Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel. Am J Hum Genet 2001; 69(2):351-360.
108. Dawson AJ, Chodirker BN, Chudley AE. Frequency of FMR1 premutations in a consecutive newborn population by PCR screening of Guthrie blood spots. Biochem Mol Med 1995; 56(1):63-69.
109. Rousseau F, Rouillard P, Morel ML et al. Prevalence of carriers of premutation-size alleles of the FMRI gene - and implications for the population genetics of the fragile X syndrome. American Journal of Human Genetics 1995; 57(5):1006-1018.
110. Hagerman PJ. The fragile X prevalence paradox. Journal of Medical Genetics 2008; 45(8):498-499.
111. Fernandez-Carvajal I, Walichiewicz P, Xiaosen X et al. Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. J Mol Diagn 2009; 11(4):324-329.
112. Song FJ, Barton P, Sleightholme V et al. Screening for fragile X syndrome: a literature review and modelling study. Health Technol Assess 2003; 7(16):1-106.
113. Otsuka S, Sakamoto Y, Siomi H et al. Fragile X carrier screening and FMR1 allele distribution in the Japanese population. Brain and Development 2010; 32(2):110-114.
114. Loesch DZ, Huggins R, Hay DA et al. Genotype-phenotype relationships in fragile X syndrome: a family study. American Journal of Human Genetics 1993; 53(5):1064-1073.
115. Hagerman RJ, Staley LW, O'Conner R et al. Learning-disabled males with a fragile X CGG expansion in the upper premutation size range. Pediatrics 1996; 97(1):122-126.
116. Loesch D, Hay D, Mulley J. Transmitting males and carrier females in fragile X-revisited. Am J Med Genet 1994; 51(4):392-399.
117. Hull C, Hagerman RJ. A study ofthe physical, behavioral and medical phenotype, including anthropometric measures, of females with fragile X syndrome. Am J Dis Child 1993; 147(11):1236-1241.
118. Riddle JE, Cheema A, Sobesky WE et al. Phenotypic involvement in females with the FMR1 gene mutation. Am J Ment Retard 1998; 102(6):590-601.
119. Loesch DZ, Huggins RM, Bui QM et al. Effect of fragile X status categories and FMRP deficits on cognitive profiles estimated by robust pedigree analysis. Am J Med Genet A 2003; 122A(l):13-23.
120. Loesch DZ, Bui QM, Grigsby J et al. Effect of the fragile X status categories and the fragile X mental retardation protein levels on executive functioning in males and females with fragile X. Neuropsychology 2003; 17(4):646-657.
121. Grigsby J, Kaye K. Behavioral Dyscontrol Scale: Manual. 2nd edition. 1996.
122. Meyers JE, Meyers KR. Rey Complex Figure Test and Recognition Trial Manual. Odessa FI.: Psychological Assessment Resources, Inc.; 1995.
123. Moore CJ, Daly EM, Schmitz N et al. A neuropsychological investigation of male premutation carriers of fragile X syndrome. Neuropsychologia 2004; 42(14):1934-1947.
124. Lachiewicz AM, Dawson DV, Spiridigliozzi GA et al. Arithmetic difficulties in females with the fragile X premutation. American Journal of Medical Genetics 2006; 140(7):665-672.
125. Keri S, BenedekG. Visualpathway deficit infemale fragile Xpremutationcarriers: apotentialendophenotype. Brain Cogn 2009; 69(2):291-295.
126. Keri S, Benedek G. The perception of biological and mechanical motion in female fragile X premutation carriers. Brain Cogn 2010; 72(2):197-201.
127. Hunsaker MR, Goodrich-Hunsaker NJ, Willemsen R et al. Temporal ordering deficits in female CGG KI mice heterozygous for the fragile X premutation. Behavioural Brain Research 2010; 213(2):263-268.
128. Minguez M, Ibanez B, Ribate MP et al. Risk of cognitive impairment in female premutation carriers of fragile X premutation: analysis by means of robust segmented linear regression models. Am J Med Genet B Neuropsychiatr Genet 2009; 150B(2):262-270.
129. Goodlin-Jones BL, Tassone F, Gane LW et al. Autistic spectrum disorder and the fragile X premutation. J Dev Behav Pediatr 2004; 25(6):392-398.
130. Loesch DZ, Huggins RM, Bui QM et al. Relationship of deficits of FMR1 gene specific protein with physical phenotype of fragile X males and females in pedigrees: a new perspective. Am J Med Genet A 2003; 118A(2):127-134.
131. Jakala P, Hanninen T, Ryynanen M et al. Fragile-X: neuropsychological test performance, CGG triplet repeat lengths and hippocampal volumes. J Clin Invest 1997; 100(2):331-338.
132. Murphy DGM, Mentis MJ, Pietrini P et al. Premutation female carriers of fragile X syndrome: a pilot study on brain anatomy and metabolism. Journal of the American Academy of Child and Adolescent Psychiatry 1999; 38(10):1294-1301.
133. Moore CJ, Daly EM, Tassone F et al. The effect of premutation of X chromosome CGG trinucleotide repeats on brain anatomy. Brain 2004; 127(Pt 12):2672-2681.
134. Adams PE, Adams JS, Nguyen DV et al. Psychological symptoms correlate with reduced hippocampal volume in fragile X premutation carriers. Am J Med Genet B Neuropsychiatr Genet 2010; 153B(3); 775-78.
135. Hessl D, Rivera S, Koldewyn K et al. Amygdala dysfunction in men with the fragile X premutation. Brain 2007; 130(2):404-416.
136. Koldewyn K, Hessl D, Adams J et al. Reduced hippocampal activation during recall is associated with elevated FMR1 mRNA and psychiatric symptoms in men with the fragile X premutation. Brain Imaging Behav 2008; 2(2):105-116.
137. Hagerman RJ, Hagerman PJ. The fragile X premutation: into the phenotypic fold. Current Opinion in Genetics and Development 2002; 12:278-283.
138. Cornish KM, Li L, Kogan CS et al. Age-dependent cognitive changes in carriers of the fragile X syndrome. Cortex 2008; 44(6):628-636.
139. Kogan C, Turk J, Hagerman RJ et al. Impact of the fragile X mental retardation 1 (FMR1) gene premutation on neuropsychiatric functioning in adult males without fragile X-associated tremor/ataxia syndrome: a controlled study. Am J Med Genet B Neuropsychiatr Genet 2008; 147B(6):859-872.
140. Cornish KM, Kogan CS, Li L et al. Lifespan changes in working memory in fragile X premutation males. Brain and Cognition 2009; 69(3):551-558.
141. Sevin M, Kutalik Z, Bergman S et al. Penetrance of marked cognitive impairment in older male carriers of the FMR1 gene premutation. Journal of Medical Genetics 2009; 46(12):818-824.
142. Hunter J, Abramowitz A, Rusin M et al. Is there evidence for neuropsychological and neurobehavioral phenotypes among adults without FXTAS who carry the FMR1 premutation? A review of current literature. Genet Med 2009; 11(2):79-89.
143. Reiss AL, Freund L, Abrams MT et al. Neurobehavioral effects of the fragile X premutation in adult women: a controlled study. American journal of human genetics 1993; 52(5):884-894.
144. Franke P, Leboyer M, Gansicke M et al. Genotype-phenotype relationship in female carriers of the premutation and full mutation of FMR-1. Psychiatry Research 1998; 80(2):113-127.
145. Al-Semaan Y, Malla AK, Lazosky A. Schizoaffective disorder in a fragile-X carrier. Australian and New Zealand Journal of Psychiatry 1999; 33(3):436-440.
146. Rodriguez-Revenga L, Madrigal I, Alegret M et al. Evidence of depressive symptoms in fragile-X syndrome premutated females. Psychiatr Genet 2008; 18(4):153-155.
147. Roberts J, Bailey D Jr., Mankowski J et al. Mood and anxiety disorders in females with the FMR1 premutation. Am J Med Genet B Neuropsychiatr Genet 2009; 150B(1):130-139.
148. Bailey DJ, Raspa M, Olmsted M et al. Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey. Am J Med Genet A 2008; 146A(16):2060-2069.
149. Hunter J, Allen E, Abramowitz A et al. Investigation of phenotypes associated with mood and anxiety among male and female fragile X premutation carriers. Behavior Genetics 2008; 38(5):493-502.
150. Allen EG, He W, Yadav-Shah M et al. A study of the distributional characteristics of FMR1 transcript levels in 238 individuals. Hum Genet 2004; 114(5):439-447.
151. Tassone F, Iwahashi C, Hagerman PJ. FMR1 RNA within the intranuclear inclusions offragile X-associated tremor/ataxia syndrome (FXTAS). RNA Biol 2004; 1(2):103-105.
152. Tassone F, Hagerman RJ, Chamberlain WD et al. Transcription of the FMR1 gene in individuals with fragile X syndrome. Am J Med Genet Fall 2000; 97(3):195-203.
153. Tassone F, Hagerman R, Taylor A et al. Clinical involvement and protein expression in individuals with the FMR1 premutation. American Journal of Medical Genetics 2000; 91(2):144-152.
154. Tassone F, Hagerman RJ, Garcia-Arocena D et al. Intranuclear inclusions in neural cells with premutation alleles in fragile X associated tremor/ataxia syndrome. Journal of Medical Genetics 2004; 41(4):e43.
155. Kenneson A, Zhang F, Hagedorn CH et al. Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum Mol Genet 2001; 10(14):1449-1454.
156. Chen LS, Tassone F, Sahota P et al. The (CGG)n repeat element within the 5' untranslated region of the FMR1 message provides both positive and negative cis effects on in vivo translation of a downstream reporter. Hum Mol Genet 2003; 12(23):3067-3074.
157. Tassone F, Beilina A, Carosi C et al. Elevated FMR1 mRNA in premutation carriers is due to increased transcription. RNA 2007; 13(4):555-562.
158. Garcia-Alegria E, Berta Ibanez, Monica Minguez et al. Analysis of FMR1 gene expression in female premutation carriers using robust segmented linear regression models. RNA 2007; 13:756-762.
159. §enturkD, Nguyen DV, Tassone F et al. Covariate adjusted correlation analysis with application to FMR1 premutation female carrier data. Biometrics 2009; 65(3):781-792.
160. Hagerman R, Greco CM, Chudley AE et al. Neuropathology and neurodegenerative features in some older male premutation carriers of fragile X syndrome. Am J Hum Genet 2001; 69(177).
161. Hagerman RJ, Hagerman PJ. Fragile X Syndrome and fragile X-associated tremor/ataxia syndrome. In: Robert D. Wells, Ashizawa T, eds. Genetic Instabilities and Neurological Diseases. 2nd edition. Houston, USA: Academic Press; 2006:165-174.
162. Berry-Kravis E, Lewin F, Wuu J et al. Tremor and ataxia in fragile X premutation carriers: blinded videotape study. Ann Neurol 2003; 53(5):616-623.
163. Leehey MA, Berry-Kravis E, Min SJ et al. Progression of tremor and ataxia in male carriers of the FMR1 premutation. Mov Disord 2007; 22(2):203-206.
164. Leehey MA, Hagerman RJ, Landau WM et al. Tremor/ataxia syndrome in fragile X carrier males. Movement Disorders 2002; 17(4):744-745.
165. Jacquemont S, Hagerman RJ, Leehey MA et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA 2004; 291(4):460-469.
166. Loesch DZ, Churchyard A, Brotchie P et al. Evidence for and a spectrum of, neurological involvement in carriers of the fragile X premutation: FXTAS and beyond. Clinical Genetics 2005; 67(5):412-417.
167. Pugliese P, Annesi G, Cutuli N et al. The fragile X premutation presenting as postprandial hypotension. Neurology 2004; 63(11):2188-2189.
168. Soontarapornchai K, Maselli R, Fenton-Farrell G et al. Abnormal nerve conduction features in fragile X premutation carriers. Archives of Neurology 2008; 65(4):495-498.
169. Adams JS, Adams PE, Nguyen D et al. Volumetric brain changes in females with fragile X-associated tremor/ataxia syndrome (FXTAS). Neurology 2007; 69(9):851-859.
170. Brunberg JA, Jacquemont S, Hagerman RJ et al. Fragile X premutation carriers: characteristic MR imaging findings of adult male patients with progressive cerebellar and cognitive dysfunction. Am J Neuroradiol 2002; 23(10):1757-1766.
171. Moris G, Arias M, Lopez MV, Alvarez V. Hyperintensity in the basis pontis: atypical neuroradiological findings in a woman with FXTAS. Movement Disorders 2010; 25(5):649-650.
172. Loesch DZ, Kotschet K, Trost, NC et al. White matter changes in basic pontis in small expansion FMR1 allele carriers with parkinsonism. Neuropsychiatric Genetics 2011; in press.
173. Greco CM, Berman RF, Martin RM et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 2006; 129(Pt 1):243-255.
174. Cohen S, Masyn K, Adams J et al. Molecular and imaging correlates of the fragile X-associated tremor/ ataxia syndrome. Neurology 2006; 67(8):1426-1431.
175. Loesch DZ, Litewka L, Brotchie P et al. Magnetic resonance imaging study in older fragile X premutation male carriers. Annals of Neurology 2005; 58(2):326-330.
176. Greco CM, Hagerman RJ, Tassone F et al. Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain 2002; 125(8):1760-1771.
177. Willemsen R, Hoogeveen-Westerveld M, Reis S et al. The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome. Hum Mol Genet 2003; 12(9):949-959.
178. Wenzel HJ, Hunsaker MR, Greco CM et al. Ubiquitin-positive intranuclear inclusions in neuronal and glial cells in a mouse model of the fragile X premutation. Brain Res 2010; 1318:155-166.
179. Grigsby J, Brega AG, Jacquemont S et al. Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS). J Neurol Sci 2006; 248(1-2):227-233.
180. Grigsby J, Brega AG, Leehey MA et al. Impairment of executive cognitive functioning in males with fragile X-associated tremor/ataxia syndrome. Mov Disord 2007; 22(5):645-650.
181. Bacalman S, Farzin F, Bourgeois JA et al. Psychiatric phenotype of the fragile X-associated tremor/ ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia. J Clin Psychiatry 2006; 67(1):87-94.
182. Bourgeois JA, Cogswell JB, Hessl D et al. Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome. Gen Hosp Psychiatry 2007; 29(4):349-356.
183. Seritan AL, Nguyen DV, Farias ST et al. Dementia in fragile X-associated tremor/ataxia syndrome (FXTAS): comparison with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2008; 147B(7):1138-1144.
184. Loesch DZ, Cook M, Litewka L et al. A low symptomatic form of neurodegeneration in younger carriers of the FMR1 premutation, manifesting typical radiological changes. Journal of Medical Genetics 2008; 45(3):179-181.
185. Loesch DZ, Litewka L, Churchyard A et al. Tremor/ataxia syndrome and fragile X premutation: diagnostic caveats. J Clin Neurosci 2007; 14(3):245-248.
186. Capelli LP, Goncalves MR, Kok F et al. Fragile X-associated tremor/ataxia syndrome: intrafamilial variability and the size of the FMR1 premutation CGG repeat. Mov Disord 2007; 22(6):866-870.
187. Greco CM, Tassone F, Garcia-Arocena D et al. Clinical and neuropathologic findings in a woman with the FMR1 premutation and multiple sclerosis. Archives of Neurology 2008; 65(8):1114-1116.
188. Zhang L, Coffey S, Lua LL et al. FMR1 premutation in females diagnosed with multiple sclerosis. J Neurol Neurosurg Psychiatry 2009; 80(7):812-814.
189. Mothersead PK, Conrad K, Hagerman RJ et al. GRAND ROUNDS: an atypical progressive dementia in a male carrier of the fragile X premutation: an example of fragile X-associated tremor/ataxia syndrome. Appl Neuropsychol 2005; 12(3):169-178.
190. Yachnis AT, Roth HL, Heilman KM. Fragile X Dementia Parkinsonism Syndrome (FXDPS). Cognitive and Behavioral Neurology 2010; 23(1):39-43. doi: 10.1097/WNN.1090b1013e3181b1096e1091b1099.
191. Chonchaiya W, Nguyen DV, Au J et al. Clinical involvement in daughters of men with fragile X-associated tremor ataxia syndrome. Clinical Genetics 2010; 78(1):39-46.
192. Brouwer JR, Huizer K, Severijnen LA et al. CGG-repeat length and neuropathological and molecular correlates in a mouse model for fragile X-associated tremor/ataxia syndrome. J Neurochem 2008; 107(6):1671-1682.
193. Tassone F, Adams J, Berry-Kravis EM et al. CGG repeat length correlates with age of onset of motor signs of the fragile X-associated tremor/ataxia syndrome (FXTAS). Am J Med Genet B Neuropsychiatr Genet 2007; 144(4):566-569.
194. Leehey MA, Berry-Kravis E, Goetz CG et al. FMR1 CGG repeat length predicts motor dysfunction in premutation carriers. Neurology 2008; 70(16 Pt 2):1397-1402.
195. Berry-Kravis E, Goetz CG, Leehey MA et al. Neuropathic features in fragile X premutation carriers. Am J Med Genet A 2007; 143(1):19-26.
196. Tassone F, Hagerman RJ, Gane LW et al. Strong similarities of the FMR1 mutation in multiple tissues: postmortem studies of a male with a full mutation and a male carrier of a premutation. American Journal of Medical Genetics 1999; 84(3):240-244.
197. Milunsky JM, Maher TA. Fragile X carrier screening and spinocerebellar ataxia in older males. American Journal of Medical Genetics 2004; 125(3):320.
198. Macpherson J, Waghorn A, Hammans S et al. Observation of an excess of fragile-X premutations in a population of males referred with spinocerebellar ataxia. Hum Genet 2003; 112(5-6):619-620.
199. Van Esch H, Dom R, Bex D et al. Screening for FMR-1 premutations in 122 older Flemish males presenting with ataxia. Eur J Hum Genet 2005; 13(1):121-123.
200. Tan EK, Zhao Y, Puong KY et al. Fragile X premutation alleles in SCA, ET and parkinsonism in an Asian cohort. Neurology 2004; 63(2):362-363.
201. Brussino A, Gellera C, Saluto A et al. FMR1 gene premutation is a frequent genetic cause of late-onset sporadic cerebellar ataxia. Neurology 2005; 64(1):145-147.
202. Garcia Arocena D, Louis ED, Tassone F et al. Screen for expanded FMR1 alleles in patients with essential tremor. Mov Disord 2004; 19(8):930-933.
203. Deng H, Le W, Jankovic J. Premutation alleles associated with Parkinson disease and essential tremor. Jama 2004; 292(14):1685-1686.
204. Kamm C, Healy DG, Quinn NP et al. The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. Brain 2005; 128(Pt 8):1855-1860.
205. Toft M, Aasly J, Bisceglio G et al. Parkinsonism, FXTAS and FMR1 premutations. Mov Disord 2005; 20(2):230-233.
206. Zuhlke C, Budnik A, Gehlken U et al. FMR1 premutation as a rare cause of late onset ataxia - evidence for FXTAS in female carriers. J Neurol 2004; 251(11):1418-1419.
207. Garland EM, Vnencak-Jones CL, Biaggioni I et al. Fragile X gene premutation in multiple system atrophy. J Neurol Sci 2004; 227(1):115-118.
208. Biancalana V, Toft M, Le Ber I et al. FMR1 premutations associated with fragile X-associated tremor/ ataxia syndrome in multiple system atrophy. Archives of Neurology 2005; 62(6):962-966.
209. Seixas AI, Maurer MH, Lin M et al. FXTAS, SCA10 and SCA17 in American patients with movement disorders. American Journal of Medical Genetics 2005; 136(1):87-89.
210. Tan EK, Zhao Y, Puong KY et al. Expanded FMR1 alleles are rare in idiopathic Parkinson's disease. Neurogenetics 2005; 6(1):51-52.
211. Jacquemont S, Farzin F, Hall D et al. Aging in individuals with the FMR1 mutation. Am J Ment Retard 2004; 109(2):154-164.
212. Kurz MW, Schlitter AM, Klenk Y et al. FMR1 alleles in Parkinson's disease: relation to cognitive decline and hallucinations, a longitudinal study. J Geriatr Psychiatry Neurol 2007; 20(2):89-92.
213. Kraff J, Tang HT, Cilia R et al. Screen for excess FMR1 premutation alleles among males with parkinsonism. Arch Neurol 2007; 64(7):1002-1006.
214. Loesch DZ, Khaniani MS, Slater HR et al. Small CGG repeat expansion alleles of FMR1 gene are associated with parkinsonism. Clinical Genetics 2009; 76(5):471-476.
215. Karmon Y, Gadoth N. Fragile X associated tremor/ataxia syndrome (FXTAS) with dementia in a female harbouring FMR1 premutation. J Neurol Neurosurg Psychiatry 2008; 79(6):738-739.
216. Hagerman RJ, Leavitt BR, Farzin F et al. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. American Journal of Human Genetics 2004; 74(5):1051-1056.
217. Berry-Kravis E, Potanos K, Weinberg D et al. Fragile X-associated tremor/ataxia syndrome in sisters related to X-inactivation. Annals of Neurology 2005; 57(1):144-147.
218. Jacquemont S, Orrico A, Galli L et al. Spastic paraparesis, cerebellar ataxia and intention tremor: a severe variant of FXTAS? Journal of Medical Genetics 2005; 42(2):e14.
219. O'Dwyer JP, Clabby C, Crown J et al. Fragile X-associated tremor/ataxia syndrome presenting in a woman after chemotherapy. Neurology 2005; 65(2):331-332.
220. Al-Hinti JT, Nagan N, Harik SI. Fragile X premutation in a woman with cognitive impairment, tremor and history of premature ovarian failure. Alzheimer Dis Assoc Disord 2007; 21(3):262-264.
221. Galvao R, Mendes-Soares L, Camara J et al. Triplet repeats, RNA secondary structure and toxic gain-of-function models for pathogenesis. Brain Res Bull 2001; 56(3-4):191-201.
222. Finsterer J. Myotonic dystrophy type 2. European Journal of Neurology 2002; 9(5):441-447.
223. Mankodi A, Thornton CA. Myotonic syndromes. Current Opinion in Neurology 2002; 15(5):545-552.
224. Khalili K, Del Valle L, Muralidharan V et al. Puralpha is essential for postnatal brain development and developmentally coupled cellular proliferation as revealed by genetic inactivation in the mouse. Mol Cell Biol 2003; 23(19):6857-6875.
225. Jin P, Duan R, Qurashi A et al. Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a Drosophila model offragile X tremor/ataxia syndrome. Neuron 2007; 55(4):556-564.
226. Garcia-Arocena D, Yang JE, Brouwer JR et al. Fibroblast phenotype in male carriers of FMR1 premutation alleles. Hum Mol Genet 2010; 19(2):299-312.
227. Paul R, Pessah IN, Gane L et al. Early onset of neurological symptoms in fragile X premutation carriers exposed to neurotoxins. Neurotoxicology 2010; 31(4):399-402.
228. Iwahashi CK, Yasui DH, An HJ et al. Protein composition of the intranuclear inclusions of FXTAS. Brain 2006; 129(Pt 1):256-271.
229. Arocena DG, Iwahashi CK, Won N et al. Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells. Hum Mol Genet 2005; 14(23):3661-3671.
230. Sellier C, Rau F, Liu Y et al. Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. The EMBO Journal 2010; 29(7):1248-1261.
231. Sellier C, Hagerman P, Willemsen R et al. DROSHA/DGCR8 sequestration by expanded CGG repeats leads to global micro-RNA processing alteration in FXTAS patients [abstract]. Paper presented at: 12th International Fragile X Conference; 2010; Detroit, MI.
232. Jin P, Zarnescu DC, Zhang F et al. RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in Drosophila. Neuron 2003; 39(5):739-747.
233. Van Dam D, Errijgers V, Kooy RF et al. Cognitive decline, neuromotor and behavioural disturbances in a mouse model for fragile-X-associated tremor/ataxia syndrome (FXTAS). Behavioural Brain Research 2005; 162(2):233-239.
234. Hashem V, Galloway JN, Mori M et al. Ectopic expression of CGG containing mRNA is neurotoxic in mammals. Hum Mol Genet 2009; 18(13):2443-2451.
235. Greco CM, Soontrapornchai K, Wirojanan J et al. Testicular and pituitary inclusion formation in fragile X associated tremor/ataxia syndrome. The Journal of Urology 2007; 177(4):1434-1437.
236. Brouwer JR, Severijnen E, de Jong FH et al. Altered hypothalamus- pituitary-adrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome. Psychoneuroendocrinology 2008; 33(6):863-873.
237. Hunsaker MR, Greco C, Tassone F et al. Rare intranuclear inclusions in the brains of three older adult males with fragile X syndrome: implications for the spectrum of fragile X-associated disorders. JNEN. under review.
238. Chen Y, Tassone F, Berman RF et al. Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration. Hum Mol Genet 2010; 19(l):196-208.
239. Ross-Inta C, Omanska-Klusek A, Wong S et al. Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndrome. Biochem J 2010; 429(3):545-552.
240. Loesch DZ, Godler DE, Evans A et al. Evidence for the toxicity of bidirectional transcripts and mitochondrial dysfunction in blood associated with small CGG expansions in the FMR1 gene in patients with parkinsonism. Genet Med 2011; Jan 25. [Epub ahead of print].
241. Ladd PD, Smith LE, Rabaia NA et al. An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals. Hum Mol Genet 2007; 16(24):3174-3187.
242. Khalil AM, Faghihi MA, Modarresi F et al. A novel RNA transcript with antiapoptotic function is silenced in fragile X syndrome. PLoS ONE 2008; 3(1):e1486.
243. Welt CK, Smith PC, Taylor AE. Evidence of early ovarian aging in fragile X premutation carriers. J Clin Endocrinol Metab 2004; 89(9):4569-4574.
244. De Caro JJ, Dominguez C, Sherman SL. Reproductive health of adolescent girls who carry the FMR1 premutation: expected phenotype based on current knowledge of fragile x-associated primary ovarian insufficiency. AnnNY Acad Sci 2008; 1135:99-111.
245. Schwartz CE, Dean J, Howard-Peebles PN et al. Obstetrical and gynecological complications in fragile X carriers: a multicenter study. Am J Med Genet 1994; 51(4):400-402.
246. Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the international collaborative POF in fragile X study- preliminary data. Am J Med Genet 1999; 83:322-325.
247. Murray A, Ennis S, MacSwiney F et al. Reproductive and menstrual history of females with fragile X expansions. Eur J Hum Genet 2000; 8(4):247-252.
248. Vianna-Morgante AM, Costa SS. Premature ovarian failure is associated with maternally and paternally inherited premutation in Brazilian families with fragile X [see comments] [letter]. American Journal of Human Genetics 2000; 67(1):254-255; discussion 256-258.
249. Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet (Semin Med Genet) 2000; 97(3):189-194.
250. Tejada MI, Garcia-Alegria E, Bilbao A et al. Analysis of the molecular parameters that could predict the risk of manifesting premature ovarian failure in female premutation carriers of fragile X syndrome. Menopause 2008; 15(5):945-949.